- Home
- MRKR vs OTLK Comparison
MRKR vs OTLK Comparison
Compare MRKR & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- OTLK
- Stock Information
- Founded
- MRKR N/A
- OTLK 2010
- Country
- MRKR United States
- OTLK United States
- Employees
- MRKR N/A
- OTLK N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRKR Health Care
- OTLK Health Care
- Exchange
- MRKR Nasdaq
- OTLK Nasdaq
- Market Cap
- MRKR 30.7M
- OTLK 35.0M
- IPO Year
- MRKR N/A
- OTLK 2016
- Fundamental
- Price
- MRKR $3.47
- OTLK $1.36
- Analyst Decision
- MRKR Strong Buy
- OTLK Strong Buy
- Analyst Count
- MRKR 1
- OTLK 7
- Target Price
- MRKR $19.00
- OTLK $40.57
- AVG Volume (30 Days)
- MRKR 91.1K
- OTLK 4.7M
- Earning Date
- MRKR 11-14-2024
- OTLK 02-12-2025
- Dividend Yield
- MRKR N/A
- OTLK N/A
- EPS Growth
- MRKR N/A
- OTLK N/A
- EPS
- MRKR N/A
- OTLK N/A
- Revenue
- MRKR $5,395,849.00
- OTLK N/A
- Revenue This Year
- MRKR $35.94
- OTLK N/A
- Revenue Next Year
- MRKR N/A
- OTLK N/A
- P/E Ratio
- MRKR N/A
- OTLK N/A
- Revenue Growth
- MRKR 79.04
- OTLK N/A
- 52 Week Low
- MRKR $2.44
- OTLK $0.87
- 52 Week High
- MRKR $6.16
- OTLK $12.85
- Technical
- Relative Strength Index (RSI)
- MRKR 50.16
- OTLK 21.15
- Support Level
- MRKR $3.47
- OTLK $1.34
- Resistance Level
- MRKR $5.95
- OTLK $1.59
- Average True Range (ATR)
- MRKR 0.63
- OTLK 0.17
- MACD
- MRKR 0.01
- OTLK 0.09
- Stochastic Oscillator
- MRKR 16.99
- OTLK 17.28
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.